logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
H

Hirotsugu Uemura

University of Osaka
H指数:48
被引数:1.4万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Evaluation of clinical prognostic factors for radium-223 therapy in castration-resistant prostate cancer with bone metastases: the KYUCOG-1901 study

评估骨转移性去势抵抗性前列腺癌接受镭-223治疗的临床预后因素：KYUCOG-1901研究

Scientific Reports
IF3.9
2026-09-040
OAAI
Atsuro Sawada; Michikazu Nakai; Masaki Shiota; Takayuki Sumiyoshi; Naoko Fujita; Takaya Murashima; Takahiro Akioka; Tomomi Kamba; Hideki Enokida; Tsukasa Igawa; Naoya Masumori; Hirotsugu Uemura; Katsuyoshi Higashijima; Kensuke Mitsunari; Hiroji Uemura; Shoji Tokunaga; Masatoshi Eto; Toshiyuki Kamoto
Efficacy of Cabozantinib in Patients With Advanced Renal Cell Carcinoma With Bone Metastasis Assessed by Modified MD Anderson Criteria: An Open-Label Phase 2 Study

卡博替尼在伴有骨转移的晚期肾细胞癌患者中的疗效评估：一项基于改良MD Anderson标准的开放标签II期研究

INTERNATIONAL JOURNAL OF UROLOGY
IF2.2
2026-05-250
OA
Hongo, Fumiya; Nakai, Yasutomo; Nozawa, Masahiro; Kato, Taigo; Kamikawa, Sadanori; Tamada, Satoshi; Yamada, Kaori; Soeda, Junpei; Tsubouchi, Ryoichi; Osaka, Tsuyoshi; Uemura, Hirotsugu
Outcomes of Nivolumab-Plus-Ipilimumab in Metastatic Renal Cell Carcinoma: Second Interim Analysis of the J-ENCORE Study

Nivolumab-Plus-Ipilimumab在转移性肾细胞癌中的疗效：J-ENCORE研究的第二次中期分析

INTERNATIONAL JOURNAL OF UROLOGY
IF2.2
2025-11-010
OAAI
Sazuka, Tomokazu; Tatsugami, Katsunori; Shirotake, Suguru; Hamamoto, Shuzo; Nozawa, Masahiro; Numakura, Kazuyuki; Mizokami, Atsushi; Kondo, Tsunenori; Naito, Sei; Abe, Takashige; Ohba, Kojiro; Kimura, Go; Onodera, Shunta; Yamaguchi, Katsumi; Uemura, Hirotsugu
Capivasertib plus abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer: CAPItello-281 Phase III study

Capivasertib 联合 Abiraterone 治疗 PTEN 缺失的转移性激素敏感性前列腺癌：CAPItello-281 III 期研究

Annals of Oncology
IF65.4
2025-10-190
OAAI
Karim Fizazi; Noel W. Clarke; Maria De Santis; Hirotsugu Uemura; Andre P. Fay; Nuri Karadurmus; Mariusz Kwiatkowski; Carlos Alvarez-Fernandez; Shusuan Jiang; Miguel Sotelo; Dominique Parslow; Niara Oliveira; Tae Gyun Kwon; Dingwei Ye; Steve Boudewijns; Pongwut Danchaivijitr; Claire Rooney; Christopher Gresty; Marc Yeste-Velasco; Jill Logan; Daniel J. George
Post-marketing surveillance of radium-223 chloride in Japanese patients with castration-resistant prostate cancer with bone metastasis—final analysis of 3-year extended follow-up focusing on bone fractures

镭-223氯化物在日本去势抵抗性前列腺癌伴骨转移患者中的上市后监测——为期3年延长随访的最终分析，重点关注骨骨折

international journal of oncology
IF2.8
2025-08-080
OAAI
Naoya Masumori; Makoto Hosono; Shunji Takahashi; Yoshiyuki Kakehi; Hirotsugu Uemura; Toshiyuki Sunaya; Kako Shimotsumagari; Yasuhiro Matsuba; Masatoshi Adachi; Haruka Kakiuchi; Seigo Kinuya
EIF2S1 in Urinary Extracellular Vesicles as a Novel Diagnostic Marker for Bladder Cancer

尿液中细胞外囊泡中的EIF2S1作为膀胱癌的新型诊断标志物

CANCER MEDICINE
IF3.1
2025-05-140
OA
Tomiyama, Eisuke; Fujita, Kazutoshi; Matsuzaki, Kyosuke; Narumi, Ryohei; Matsushita, Makoto; Hayashi, Yujiro; Hashimoto, Mamoru; Kato, Taigo; Hatano, Koji; Kawashima, Atsunari; Minami, Takafumi; Takao, Tetsuya; Takada, Shingo; Uemura, Hirotsugu; Adachi, Jun; Tomonaga, Takeshi; Nonomura, Norio
Real-world outcomes with avelumab plus axitinib in patients with advanced renal cell carcinoma in Japan: subgroup analyses from the J-DART2 study by International Metastatic Renal Cell Carcinoma Database Consortium risk classification

日本晚期肾细胞癌患者接受阿维鲁姆单抗联合阿昔替尼治疗的实际世界结局：基于国际转移性肾细胞癌数据库联盟风险分类的J-DART2研究亚组分析

international journal of oncology
IF2.8
2025-02-110
OA
Furukawa, Junya; Kato, Taigo; Yamasaki, Toshinari; Monji, Keisuke; Tanaka, Toshiaki; Tsuchiya, Norihiko; Miyagawa, Tomoaki; Yaegashi, Hiroshi; Sano, Tomoyasu; Karashima, Takashi; Fujita, Kazutoshi; Hori, Jun-ichi; Ito, Takayuki; Kajita, Masahiro; Tomita, Yoshihiko; Shinohara, Nobuo; Eto, Masatoshi; Oya, Mototsugu; Uemura, Hirotsugu
Phase 3 Study of Talazoparib Plus Enzalutamide Versus Placebo Plus Enzalutamide as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer: TALAPRO-2 Japanese Subgroup Analysis

III期研究：talazoparib 联合 enzalutamide 与安慰剂联合 enzalutamide 作为一线治疗转移性去势抵抗性前列腺癌患者的比较：TALAPRO-2 日本亚组分析

CANCER MEDICINE
IF3.1
2024-12-310
OA
Matsubara, Nobuaki; Miyake, Hideaki; Uemura, Hiroji; Mizokami, Atsushi; Kikukawa, Hiroaki; Kosaka, Takeo; Nishimura, Kazuo; Nakamura, Motonobu; Kobayashi, Kazuki; Komaru, Atsushi; Mori, Yuko; Toyoizumi, Shigeyuki; Hori, Natsuki; Umeyama, Yoshiko; Uemura, Hirotsugu
Post Hoc Analysis of Rapid and Deep Prostate-specific Antigen Decline and Patient-reported Health-related Quality of Life in SPARTAN and TITAN Patients with Advanced Prostate Cancer

SPARTAN和TITAN晚期前列腺癌患者快速和深度前列腺特异性抗原下降和患者报告的健康相关生活质量的事后分析

EUROPEAN UROLOGY ONCOLOGY
IF9.3
2024-08-015
PRE
Small, Eric J.; Chi, Kim N.; Chowdhury, Simon; Bevans, Katherine B.; Bhaumik, Amitabha; Saad, Fred; Ha Chung, Byung; Karsh, Lawrence I.; Oudard, Stephane; De Porre, Peter; Brookman-May, Sabine D.; McCarthy, Sharon A.; Mundle, Suneel D.; Uemura, Hirotsugu; Smith, Matthew R.; Agarwal, Neeraj
Targeted Investigational Treatment Analysis of Novel Anti-androgen (TITAN) study: ultralow prostate-specific antigen decline with apalutamide plus androgen-deprivation therapy
BJU INTERNATIONAL
IF4.4
2024-06-286
OA
Merseburger, Axel S.; Agarwal, Neeraj; Bjartell, Anders; Uemura, Hirotsugu; Soto, Alvaro Juarez; Bhaumik, Amitabha; Boehm, Juergen; Tran, Nguyen; Krochmann, Nils; Nematian-Samani, Mehregan; Mundle, Suneel D.; Brookman-May, Sabine D.; Lopez-Gitlitz, Angela; McCarthy, Sharon A.; Chi, Kim; Chowdhury, Simon
C-Reactive Protein-Albumin Ratio Predicts Objective Response to Enfortumab Vedotin in Metastatic Urothelial Carcinoma
TARGETED ONCOLOGY
IF4
2024-05-285
PRE
Uchimoto, Taizo; Matsuda, Takuya; Komura, Kazumasa; Fukuokaya, Wataru; Adachi, Takahiro; Hirasawa, Yosuke; Hashimoto, Takeshi; Yoshizawa, Atsuhiko; Saruta, Masanobu; Hashimoto, Mamoru; Higashio, Takuya; Tsuchida, Shuya; Nishimura, Kazuki; Tsujino, Takuya; Nakamura, Ko; Fukushima, Tatsuo; Nishio, Kyosuke; Yamamoto, Shutaro; Iwatani, Kosuke; Urabe, Fumihiko; Mori, Keiichiro; Yanagisawa, Takafumi; Tsuduki, Shunsuke; Takahara, Kiyoshi; Inamoto, Teruo; Miki, Jun; Fujita, Kazutoshi; Kimura, Takahiro; Ohno, Yoshio; Shiroki, Ryoichi; Uemura, Hirotsugu; Azuma, Haruhito
Durable Response to Enfortumab Vedotin Compared to Re-challenging Chemotherapy in Metastatic Urothelial Carcinoma After Checkpoint Inhibitors
TARGETED ONCOLOGY
IF4
2024-03-285
PRE
Uchimoto, Taizo; Tsuchida, Shuya; Komura, Kazumasa; Fukuokaya, Wataru; Adachi, Takahiro; Hirasawa, Yosuke; Hashimoto, Takeshi; Yoshizawa, Atsuhiko; Saruta, Masanobu; Hashimoto, Mamoru; Higashio, Takuya; Matsuda, Takuya; Nishimura, Kazuki; Tsujino, Takuya; Nakamura, Ko; Fukushima, Tatsuo; Nishio, Kyosuke; Yamamoto, Shutaro; Iwatani, Kosuke; Urabe, Fumihiko; Mori, Keiichiro; Yanagisawa, Takafumi; Tsuduki, Shunsuke; Takahara, Kiyoshi; Inamoto, Teruo; Miki, Jun; Fujita, Kazutoshi; Kimura, Takahiro; Ohno, Yoshio; Shiroki, Ryoichi; Uemura, Hirotsugu; Azuma, Haruhito

研究方向

暂未获取到该数据
M
Marco A. De Velasco
H 指数:37论文数:284被引数:4,300
K
Kazuto Nishio
H 指数:81论文数:1,116被引数:2.2万
K
Kazuhiro Yoshikawa
H 指数:29论文数:266被引数:3,124
M
Masahiro Nozawa
H 指数:22论文数:237被引数:1,838
K
Kazuhiro Yoshimura
H 指数:25论文数:242被引数:2,253
Y
Yurie Kura
H 指数:11论文数:101被引数:398
N
Naomi Ando
H 指数:5论文数:107被引数:175
K
Kazuko Sakai
H 指数:52论文数:614被引数:8,320
N
Nobutaka Shimizu
H 指数:0论文数:1被引数:6
Y
Yuji Hatanaka
H 指数:24论文数:213被引数:2,219